People with Cushing’s syndrome may experience lasting fatigue, reduced work ability, and disability years after treatment, including during remission, a new study shows. Researchers found that people with both active Cushing’s and disease in remission reported poor work ability. Among those in remission, fatigue and disability were also common, showing…
News
Japanese children with Cushing’s disease often went years before receiving a diagnosis, but surgery led to remission in most of those with outcome data. Measures of growth and body mass index also improved during follow-up, a study suggests. Researchers noted that although the…
Long-term use of corticosteroids may cause iatrogenic Cushing’s syndrome, a side effect of the medication that can lead to noticeable changes such as a rounded, “moon-shaped” face, according to a case report from India. In the report describing five patients, all but one…
Serious infections requiring hospitalization remain a long-term concern in Cushing’s syndrome, even after the disease goes into remission, according to a real-world study that followed more than 600 patients for about 13 years. Researchers found that adults with Cushing’s syndrome were more than twice as likely as matched people without…
Although rare, researchers say that recurrent Cushing’s disease can be caused by tumor cells accidentally left in the sphenoid sinus — an air-filled space behind the nose — during surgery to remove a tumor from the brain’s pituitary gland through the nasal passages. That’s what happened to a young…
Corcept Therapeutics has resubmitted its application to the U.S. Food and Drug Administration (FDA) seeking approval of relacorilant to treat endogenous Cushing’s syndrome, with new analyses as requested by the agency. The company submitted its initial new drug…
An 18-month-old girl developed treatment-related Cushing’s syndrome after prolonged use of a high-potency topical steroid cream prescribed for diaper rash, according to a recent case report. The parents had sought treatment after the toddler gained about 6 kg, or slightly more than 13 pounds, over three months. The child also…
Lundbeck’s experimental therapy, asedebart, brought cortisol levels back to normal in most adults with Cushing’s disease and was generally well tolerated when given as an intravenous (into-the-vein) infusion, according to preliminary data from the first part of an ongoing Phase 2 clinical trial. The BalanCeD (NCT06471829) study,…
Treatment with Korlym (mifepristone) may help lower blood sugar and promote weight loss in people with hard-to-control diabetes and high cortisol levels who are also taking medications targeting GLP-1, according to a new analysis of data from dozens of patients in the CATALYST clinical trial. Corcept Therapeutics, the…
Crinetics Pharmaceuticals, along with several patient groups, has launched the Everyday Advocacy initiative to help people with Cushing’s syndrome and other endocrine, or hormone-related, conditions better understand their diseases and take an active role in their care. Developed with input from several advocacy partners — including the…
Recent Posts
- Fatigue, work limits may persist years after Cushing’s syndrome treatment
- Missing the symptoms of mild dehydration
- Japanese children face years-long delays in Cushing’s disease diagnosis
- What happens when I push past my limits with Cushing’s disease
- Long-term corticosteroid use caused Cushing’s in 5 patients: Report
- Stuck at the intersection of anxiety and insomnia
- Cushing’s syndrome greatly raises risk of hospitalization for infections
- Tumor cells left behind in surgery can cause Cushing’s recurrence, per report
- Building strength, even with Cushing’s, so I can be there for my daughter
- Corcept gives FDA new relacorilant data in resubmitted application